Very interesting article, Redant, thank you for posting.....
I found this segment from the article interesting,
“When it comes to M&A, we continue to look for opportunities,” he (J&J CEO Joaquin Duato) added. “And when it comes to medtech … we look forward to growing in areas that are close to where we are today: vision, cardiovascular, surgery, and also high-growth segments in orthopedics.” (emphasis my own)
When the dust settles and we have more and more patients reproducing the astounding results seen in the first 21 patients I believe there is going to be a major battle encompassing not only the current incumbents in the TAVR space but also outside companies looking to enter the TAVR and SAVR space. The reason I believe this is simple..... The DurAVR has an awesome opportunity to take the ENTIRE TAVR market. It is the final battle. Whoever owns the DurAVR owns the TAVR space.
AVR Price at posting:
$21.46 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)